RKDA vs. NCRA, ORIS, IVP, CEAD, SEED, SANW, SISI, EDBL, AAGR, and YTEN
Should you be buying Arcadia Biosciences stock or one of its competitors? The main competitors of Arcadia Biosciences include Nocera (NCRA), Oriental Rise (ORIS), Inspire Veterinary Partners (IVP), CEA Industries (CEAD), Origin Agritech (SEED), S&W Seed (SANW), Shineco (SISI), Edible Garden (EDBL), African Agriculture (AAGR), and Yield10 Bioscience (YTEN). These companies are all part of the "agriculture" industry.
Arcadia Biosciences vs. Its Competitors
Arcadia Biosciences (NASDAQ:RKDA) and Nocera (NASDAQ:NCRA) are both small-cap agriculture companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
In the previous week, Nocera's average media sentiment score of 0.64 beat Arcadia Biosciences' score of 0.00 indicating that Nocera is being referred to more favorably in the news media.
Nocera has a net margin of -12.70% compared to Arcadia Biosciences' net margin of -38.34%. Arcadia Biosciences' return on equity of -16.94% beat Nocera's return on equity.
17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 1.3% of Nocera shares are owned by institutional investors. 1.8% of Arcadia Biosciences shares are owned by company insiders. Comparatively, 5.3% of Nocera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Arcadia Biosciences has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Nocera has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
Arcadia Biosciences presently has a consensus price target of $6.00, indicating a potential upside of 26.32%. Given Arcadia Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcadia Biosciences is more favorable than Nocera.
Nocera has higher revenue and earnings than Arcadia Biosciences. Nocera is trading at a lower price-to-earnings ratio than Arcadia Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Arcadia Biosciences beats Nocera on 8 of the 15 factors compared between the two stocks.
Get Arcadia Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcadia Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:RKDA) was last updated on 7/4/2025 by MarketBeat.com Staff
